Clinical trial · Observational
The Research Value of Multi-omics and Multi-modal Information in the Diagnosis and Treatment of Urinary System Tumors
NCT06490211CI-TRIAL-00078592recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Obtain puncture or surgically removed tumor tissue samples from patients with urinary tract tumors and perform RNA-sequencing, Single-cell RNA-sequence, Spatial Transcriptomics, Proteomics, and Intratumoral Microbiome.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Urinary System Carcinoma | Urinary System Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- progression-free survival
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients were treated for bladder cancer, kidney cancer, and prostate cancer in Wuhan Union Hospital from January 2024 to January 2026; 2. Aged \> 18 years old; 3. Urinalysis, urine exfoliated cells, ultrasound, CT, and MR examinations indicated the above tumors; 4. Tissue biopsy pathological examination confirmed the diagnosis of the above tumors. Exclusion Criteria: 1. Poor image quality; 2. Incomplete clinical data or loss of follow-up; 3. Presence of another primary malignant tumor other than urinary tract tumor; 4. Unclear pathological diagnosis
References
Publications (0)
Data not yet available
No reference posted for this study.